Literature DB >> 11738666

Recurrence of convexity meningiomas: tumor cells in the arachnoid membrane.

H Kamitani1, H Masuzawa, I Kanazawa, T Kubo.   

Abstract

BACKGROUND: It remains open to debate why totally removed benign meningiomas recur. Two recurrent cases forced us to reconsider something corresponding to their recurrence that we had overlooked during Simpson grade I surgery.
METHODS: This study is based on 24 recent and 9 earlier cases in which benign convexity meningiomas were totally removed by Simpson's grade I surgery. Tough or thick arachnoid membranes continuing to normal arachnoid membranes and contiguous to meningiomas but different from dura mater were encountered in 11 recent and at least 2 earlier cases. Such thick arachnoid membranes were left in place or only partially resected in two earlier cases but extensively resected in all recent cases.
RESULTS: Light microscopy showed clusters of meningioma cells not in the removed dura mater but in the thick arachnoid membranes of an earlier case and 10 out of the 11 recent cases. Six and twelve years after initial surgery, recurrence of the 2 earlier cases was confirmed at subsequent surgery or diagnosed by neuro-imaging. By contrast, neuro-imaging from 30 to 132 months after initial surgery showed no recurrence in the 10 recent cases. A follow-up study over 5 years showed a significant difference in recurrence between Simpson's grade I surgery with and without extensive removal of surrounding thick arachnoid membranes (Fisher's exact test: p < 0.05).
CONCLUSION: This study emphasizes the possibility that thick arachnoid membranes contiguous to meningiomas and continuous to normal arachnoid membranes, involving clusters of tumor cells, may relate to meningioma recurrence.

Entities:  

Mesh:

Year:  2001        PMID: 11738666     DOI: 10.1016/s0090-3019(01)00582-1

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  9 in total

1.  MMP-9 expression in meningiomas: a prognostic marker for recurrence risk?

Authors:  V Barresi; E Vitarelli; G Tuccari; G Barresi
Journal:  J Neurooncol       Date:  2010-07-21       Impact factor: 4.130

2.  Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.

Authors:  Davide Schiffer; Chiara Ghimenti; Valentina Fiano
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

3.  Histopathological Investigation of Meningioma Capsule with Respect to Tumor Cell Invasion.

Authors:  Takashi Sugawara; Daisuke Kobayashi; Taketoshi Maehara
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-08-10       Impact factor: 2.036

4.  Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density.

Authors:  Valeria Barresi; Enrica Vitarelli; Serenella Cerasoli
Journal:  Virchows Arch       Date:  2009-03-19       Impact factor: 4.064

Review 5.  Meningioma Tumor Microenvironment.

Authors:  Sajad Sahab-Negah; Ali Gorji
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas.

Authors:  Masaki Okada; Keisuke Miyake; Yoshihito Matsumoto; Nobuyuki Kawai; Katsuzo Kunishio; Seigo Nagao
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

7.  The cell growth inhibitory transcription factor C/EBPdelta is expressed in human meningiomas in association with low histological grade and proliferation index.

Authors:  V Barresi; E Vitarelli; S Cerasoli; G Barresi
Journal:  J Neurooncol       Date:  2009-10-06       Impact factor: 4.130

8.  Outcomes of Preserving the Hypertrophic Arachnoid Membrane in the Brain-meningioma Interface: Long-term Follow-up.

Authors:  Yoko Nakasu; Koichi Mitsuya; Satoshi Nakasu; Shoichi Deguchi; Nakamasa Hayashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-10-29       Impact factor: 1.742

9.  Symptom burden and surgical outcome in non-skull base meningiomas.

Authors:  Tobias Mederer; Sebastian Schachinger; Katharina Rosengarth; Anja Brosig; Karl-Michael Schebesch; Christian Doenitz; Nils-Ole Schmidt; Martin Andreas Proescholdt
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.